The trajectory of Viagra presents a complex picture for investors. While the initial release generated massive profits, the end of its exclusive rights opened the avenue to cheaper competitors, dramatically reducing sales. This poses a particular challenge for drug manufacturers relying on comparable blockbuster medications, suggesting that a unque

The history of Viagra, and its developer copyright, presents a intriguing case study for investors. Initially a blockbuster drug, generating billions in sales , its patent expiration created a flood of lower-priced alternatives , significantly diminishing its position . While specific pharmaceutical companies may attempt to capitalize on similar co